Last reviewed · How we verify
Placebo to tulisokibart
Placebo to tulisokibart is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development.
Placebo to tulisokibart does not have an active pharmacological mechanism as it is a placebo.
At a glance
| Generic name | Placebo to tulisokibart |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
A placebo is designed to have no therapeutic effect and is used as a control in clinical trials to compare against the active drug, tulisokibart, to determine its efficacy and safety.
Approved indications
Common side effects
Key clinical trials
- A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013) (PHASE2)
- Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015) (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) (PHASE3)
- A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) (PHASE3)
- A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) (PHASE2)
- Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012) (PHASE2)
- Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) (PHASE3)
- Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to tulisokibart CI brief — competitive landscape report
- Placebo to tulisokibart updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Placebo to tulisokibart
What is Placebo to tulisokibart?
How does Placebo to tulisokibart work?
Who makes Placebo to tulisokibart?
What development phase is Placebo to tulisokibart in?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Compare: Placebo to tulisokibart vs similar drugs
- Pricing: Placebo to tulisokibart cost, discount & access